Glipizide

Limits on what this shows

• Why no grade: No study measuring direct mitochondrial structure, membrane integrity, electron transport, or biogenesis effects of glipizide was located. The one glipizide-specific in vitro genotoxicity finding (nuclear DNA damage in adipocytes, see Oxidative stress) addresses nuclear, not mitochondrial, damage and was not extended here to avoid overstating it. No circulating consumer claim specifically alleging glipizide harms mitochondria was located. Both conditions for UNGRADED are met.

Tooling note

Searched via WebSearch and WebFetch across PubMed, Europe PMC, and NCBI Bookshelf phrasings before this session's search budget was exhausted; a PMC review of anti-diabetic drug-microbiome/metabolic interactions could not be opened (bot-verification page) and may be worth re-checking.

Limits on what this shows

• Key negative/null findings: Fatima et al., Mol Biol Rep 2021 (in vitro, 3T3-L1 mouse adipocytes, glipizide 180 µM): significantly increased DNA damage (comet assay, Olive Tail Moment, p<0.001) versus untreated cells, worse in senescent than mature adipocytes, with dysregulated RAN (nucleocytoplasmic transport) gene expression. This runs opposite to the human study's direction.
• At-risk subgroups: Not established; the in vitro finding was concentration- and senescence-dependent, not linked to any defined patient subgroup.
• Counter-evidence: The human study had no placebo/control arm on therapy (only a non-diabetic comparator group at baseline), so the antioxidant-marker improvement cannot be separated from the effect of correcting hyperglycemia itself: confounding by indication is presumed, not excluded. The in vitro concentration (180 µM) substantially exceeds typical clinical plasma exposure, limiting direct clinical relevance.

Regulatory status

Not addressed in the FDA/DailyMed label.

Population evidence

Malam et al., Int J Basic Clin Pharmacol 2014;3(6): longitudinal study, 30 newly diagnosed type 2 diabetes patients started on glipizide monotherapy compared with 30 non-diabetic controls. After 3 months of glipizide, malondialdehyde (MDA, a lipid-peroxidation marker) decreased significantly and superoxide dismutase (SOD) and catalase increased significantly versus pre-treatment baseline (paired analysis; exact effect sizes not given in the abstract).

Mechanism

No direct antioxidant mechanism for glipizide is established; the improvement is plausibly a downstream effect of improved glycemic control (hyperglycemia itself drives oxidative stress) rather than a direct pharmacologic antioxidant action of the drug.

Counter-evidence held on record

Neither direction is established for clinical practice. This is not evidence that glipizide protects against oxidative stress, nor that it causes it; it is disclosed as genuinely conflicting, low-certainty evidence and must not be presented to consumers as either a benefit or a deficiency-style claim.

Limits on what this shows

• Why no grade: No glipizide-specific or sulfonylurea-class-specific study of copper status was located. General type 2 diabetes trace-mineral studies exist, but they describe the disease population, not a glipizide treatment effect, and per confounding-by-indication rules cannot be attributed to the drug. No circulating claim specifically blaming glipizide or sulfonylureas for copper depletion was located. Both conditions for UNGRADED are met.

Tooling note

Searched via PubMed/DailyMed/general web search phrasings ("glipizide copper," "sulfonylurea trace mineral"); no drug-attributable source surfaced.

Limits on what this shows

• Why no grade: No glipizide-specific or sulfonylurea-class-specific study of iron status was located. The documented hemolytic anemia risk (see Oxygen delivery/utilization) is a hematologic adverse effect, not iron deficiency, and is not used here to support an iron grade per the rule that anemia is not itself a nutrient deficiency. No circulating claim specifically alleging glipizide-driven iron deficiency was located. Both conditions for UNGRADED are met.

Tooling note

Same search channels as Copper, above; general T2DM trace-mineral literature found but not drug-attributable.

Limits on what this shows

• Why no grade: No glipizide-specific microbiome study was located. Available antidiabetic-drug-microbiome literature located by title concentrates on metformin, acarbose, and SGLT2 inhibitors; a review covering bi-directional drug-microbiome interactions of antidiabetics broadly could not be opened to check for sulfonylurea/glipizide-specific content. No circulating consumer claim specifically alleging glipizide disrupts the gut microbiome was located. Both conditions for UNGRADED are met.

Tooling note

This category's search was constrained by this session's WebSearch budget being exhausted (a shared, session-wide limit) after one phrasing, and by a PMC article being blocked behind a bot-verification page on repeated WebFetch attempts. This is a disclosed tooling limitation, not a confirmed absence of literature; it should be re-checked in a future revision with a fresh search budget.

Limits on what this shows

• Key negative/null findings: Outside G6PD deficiency, glipizide is not associated with reduced hemoglobin, hematocrit, or oxygen delivery in the sources opened for this review.
• At-risk subgroups: Patients with known or unscreened G6PD deficiency (higher population prevalence in individuals of African, Mediterranean, Middle Eastern, and Southeast Asian ancestry).
• Counter-evidence: This is a rare, case-level signal; no controlled incidence data specific to glipizide were located in sources opened for this review.

Regulatory status

Stated directly in the glipizide/Glucotrol XL FDA labels: "Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia," with a recommendation to consider a non-sulfonylurea alternative.

Population evidence

Label-level postmarketing hematologic reactions for sulfonylureas as a class include hemolytic anemia, aplastic anemia, thrombocytopenia, leukopenia, agranulocytosis, and pancytopenia; StatPearls corroborates the G6PD-specific hemolysis mechanism for sulfonylureas including glipizide.

Mechanism

In G6PD-deficient red cells, reduced NADPH-dependent antioxidant capacity leaves cells vulnerable to oxidative hemolysis when exposed to certain drugs, including sulfonylureas.

Counter-evidence held on record

This is a hematologic adverse effect from an enzyme-deficiency drug interaction, not an iron, B12, or folate deficiency. Anemia in this context should not be treated as a nutrient-deficiency finding, and no iron or B-vitamin repletion is implied or supported; the relevant action is G6PD status awareness and, if hemolysis occurs, prompt discontinuation and hematology evaluation.

Limits on what this shows

• Why no grade: No study measuring mitochondrial ATP synthesis or cellular energy output specifically for glipizide was located. No circulating consumer claim specifically tying glipizide to low energy/ATP output (distinct from generic diabetes-fatigue framing) was located. Both conditions for UNGRADED are met.

Tooling note

Searched via the same channels as Mitochondrial burden, above, within this review's constrained tooling window.